Neoadjuvant treatment sequencing adds value to the care of patients with operable pancreatic cancer

Elliot A. Asare, Douglas B. Evans, Beth A. Erickson, Murad Aburajab, Parag Tolat, Susan Tsai

Research output: Contribution to journalReview article

Abstract

Treatment sequencing for resectable pancreatic cancer remains controversial and there is lack of level one evidence comparing neoadjuvant versus adjuvant strategies. However, a comparison of the cost-effectiveness analysis of the treatment strategies may help to better define the healthcare value of each approach. This review will highlight the rationale for multimodality therapy in the treatment of pancreatic cancer, discuss the advantages and disadvantages of adjuvant therapy, and conceptualize the cost-effectiveness of a neoadjuvant approach with regard to healthcare value. J. Surg. Oncol. 2016;114:291–295.

Original languageEnglish (US)
Pages (from-to)291-295
Number of pages5
JournalJournal of Surgical Oncology
Volume114
Issue number3
DOIs
StatePublished - Sep 1 2016
Externally publishedYes

Fingerprint

Neoadjuvant Therapy
Pancreatic Neoplasms
Patient Care
Cost-Benefit Analysis
Delivery of Health Care
Therapeutics

Keywords

  • cost-effectiveness
  • healthcare value
  • neoadjuvant therapy
  • pancreatic cancer

ASJC Scopus subject areas

  • Surgery
  • Medicine(all)
  • Oncology

Cite this

Asare, E. A., Evans, D. B., Erickson, B. A., Aburajab, M., Tolat, P., & Tsai, S. (2016). Neoadjuvant treatment sequencing adds value to the care of patients with operable pancreatic cancer. Journal of Surgical Oncology, 114(3), 291-295. https://doi.org/10.1002/jso.24316

Neoadjuvant treatment sequencing adds value to the care of patients with operable pancreatic cancer. / Asare, Elliot A.; Evans, Douglas B.; Erickson, Beth A.; Aburajab, Murad; Tolat, Parag; Tsai, Susan.

In: Journal of Surgical Oncology, Vol. 114, No. 3, 01.09.2016, p. 291-295.

Research output: Contribution to journalReview article

Asare, EA, Evans, DB, Erickson, BA, Aburajab, M, Tolat, P & Tsai, S 2016, 'Neoadjuvant treatment sequencing adds value to the care of patients with operable pancreatic cancer', Journal of Surgical Oncology, vol. 114, no. 3, pp. 291-295. https://doi.org/10.1002/jso.24316
Asare, Elliot A. ; Evans, Douglas B. ; Erickson, Beth A. ; Aburajab, Murad ; Tolat, Parag ; Tsai, Susan. / Neoadjuvant treatment sequencing adds value to the care of patients with operable pancreatic cancer. In: Journal of Surgical Oncology. 2016 ; Vol. 114, No. 3. pp. 291-295.
@article{b2c68e7348b2415f821b1e7d1eee477f,
title = "Neoadjuvant treatment sequencing adds value to the care of patients with operable pancreatic cancer",
abstract = "Treatment sequencing for resectable pancreatic cancer remains controversial and there is lack of level one evidence comparing neoadjuvant versus adjuvant strategies. However, a comparison of the cost-effectiveness analysis of the treatment strategies may help to better define the healthcare value of each approach. This review will highlight the rationale for multimodality therapy in the treatment of pancreatic cancer, discuss the advantages and disadvantages of adjuvant therapy, and conceptualize the cost-effectiveness of a neoadjuvant approach with regard to healthcare value. J. Surg. Oncol. 2016;114:291–295.",
keywords = "cost-effectiveness, healthcare value, neoadjuvant therapy, pancreatic cancer",
author = "Asare, {Elliot A.} and Evans, {Douglas B.} and Erickson, {Beth A.} and Murad Aburajab and Parag Tolat and Susan Tsai",
year = "2016",
month = "9",
day = "1",
doi = "10.1002/jso.24316",
language = "English (US)",
volume = "114",
pages = "291--295",
journal = "Journal of Surgical Oncology",
issn = "0022-4790",
publisher = "Wiley-Liss Inc.",
number = "3",

}

TY - JOUR

T1 - Neoadjuvant treatment sequencing adds value to the care of patients with operable pancreatic cancer

AU - Asare, Elliot A.

AU - Evans, Douglas B.

AU - Erickson, Beth A.

AU - Aburajab, Murad

AU - Tolat, Parag

AU - Tsai, Susan

PY - 2016/9/1

Y1 - 2016/9/1

N2 - Treatment sequencing for resectable pancreatic cancer remains controversial and there is lack of level one evidence comparing neoadjuvant versus adjuvant strategies. However, a comparison of the cost-effectiveness analysis of the treatment strategies may help to better define the healthcare value of each approach. This review will highlight the rationale for multimodality therapy in the treatment of pancreatic cancer, discuss the advantages and disadvantages of adjuvant therapy, and conceptualize the cost-effectiveness of a neoadjuvant approach with regard to healthcare value. J. Surg. Oncol. 2016;114:291–295.

AB - Treatment sequencing for resectable pancreatic cancer remains controversial and there is lack of level one evidence comparing neoadjuvant versus adjuvant strategies. However, a comparison of the cost-effectiveness analysis of the treatment strategies may help to better define the healthcare value of each approach. This review will highlight the rationale for multimodality therapy in the treatment of pancreatic cancer, discuss the advantages and disadvantages of adjuvant therapy, and conceptualize the cost-effectiveness of a neoadjuvant approach with regard to healthcare value. J. Surg. Oncol. 2016;114:291–295.

KW - cost-effectiveness

KW - healthcare value

KW - neoadjuvant therapy

KW - pancreatic cancer

UR - http://www.scopus.com/inward/record.url?scp=84983364793&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84983364793&partnerID=8YFLogxK

U2 - 10.1002/jso.24316

DO - 10.1002/jso.24316

M3 - Review article

C2 - 27264017

AN - SCOPUS:84983364793

VL - 114

SP - 291

EP - 295

JO - Journal of Surgical Oncology

JF - Journal of Surgical Oncology

SN - 0022-4790

IS - 3

ER -